Two Sigma Advisers
CGEM icon

Two Sigma Advisers’s Cullinan Oncology CGEM Stock Holding History

Two Sigma Advisers’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-129,809
Closed -$1.34M – 409
2025
Q4 		$1.34M Buy
129,809
+92,509
+248% +$834K ﹤0.01% 1340
2025
Q3 		$221K Buy
+37,300
New +$273K ﹤0.01% 2096
2025
Q2 		– Sell
-25,100
Closed -$190K – 2340
2025
Q1 		$190K Buy
25,100
+3,200
+15% +$30.7K ﹤0.01% 2152
2024
Q4 		$267K Buy
21,900
+4,000
+22% +$57.5K ﹤0.01% 2027
2024
Q3 		$300K Sell
17,900
-2,900
-14% -$51.4K ﹤0.01% 1908
2024
Q2 		$363K Buy
20,800
+1,200
+6% +$25.6K ﹤0.01% 2001
2024
Q1 		$334K Sell
19,600
-19,000
-49% -$294K ﹤0.01% 2030
2023
Q4 		$393K Buy
+38,600
New +$342K ﹤0.01% 2010
2022
Q4 		– Sell
-15,000
Closed -$192K – 2529
2022
Q3 		$192K Buy
+15,000
New +$202K ﹤0.01% 2214

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Two Sigma Advisers's CGEM Position: Q1 2026 in Review

Two Sigma Advisers sold out of Cullinan Oncology (CGEM) in Q1 2026, closing a stake of 129,809 shares — an estimated $1.34M sold.

Two Sigma Advisers first reported a position in CGEM in Q3 2022 and held it in 9 quarters. The position peaked at $1.34M in Q4 2025. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Two Sigma Advisers reported no remaining Cullinan Oncology position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 129,809 Cullinan Oncology shares in Q1 2026, an estimated $1.34M.
  • Two Sigma Advisers first reported a position in Cullinan Oncology in Q3 2022 and held it in 9 quarters.
  • Two Sigma Advisers's Cullinan Oncology position peaked at $1.34M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.